Chardan Healthcare Acquisition Corp. (CHAC) financial statements (2021 and earlier)
Company profile
| Business Address |
17 STATE STREET, 16TH FLOOR NEW YORK, NY 10004 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 6/30/2019 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 82 | 1 | ||
| Cash and cash equivalents | 72 | 1 | ||
| Short-term investments | 10 | |||
| Restricted cash and investments | 0 | |||
| Receivables | 0 | |||
| Prepaid expense | 0 | |||
| Other current assets | 2 | |||
| Total current assets: | 85 | 1 | ||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | 1 | ✕ | ||
| Property, plant and equipment | 2 | |||
| Long-term investments and receivables | 71 | |||
| Long-term investments | 71 | |||
| Deposits noncurrent assets | 0 | |||
| Other undisclosed noncurrent assets | 5 | 0 | ||
| Total noncurrent assets: | 8 | 71 | ||
| TOTAL ASSETS: | 92 | 72 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 3 | 0 | ||
| Accounts payable | 3 | |||
| Taxes payable | 0 | |||
| Debt | 0 | |||
| Other liabilities | 3 | |||
| Other undisclosed current liabilities | 0 | |||
| Total current liabilities: | 6 | 0 | ||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation, including: | 1 | |||
| Other undisclosed long-term debt and lease obligation | 1 | |||
| Liabilities, other than long-term debt | 1 | 1 | ||
| Due to related parties | 1 | |||
| Business combination, contingent consideration, liability | 1 | |||
| Total noncurrent liabilities: | 1 | 1 | ||
| Total liabilities: | 8 | 1 | ||
| Temporary equity, carrying amount | 66 | |||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent | 84 | 5 | ||
| Common stock | 0 | 0 | ||
| Additional paid in capital | 127 | 5 | ||
| Accumulated other comprehensive loss | (42) | |||
| Retained earnings | 0 | |||
| Total stockholders' equity: | 84 | 5 | ||
| TOTAL LIABILITIES AND EQUITY: | 92 | 72 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 6/30/2019 | ||
|---|---|---|---|
| Gross profit: | 1 | ||
| Operating expenses | (22) | (0) | |
| Other undisclosed operating loss | (1) | ||
| Operating loss: | (22) | (0) | |
| Nonoperating income (Investment Income, Nonoperating) | 2 | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 1 | ||
| Income (loss) from continuing operations before income taxes: | (21) | 0 | |
| Income tax expense | (2) | (0) | |
| Income (loss) before gain (loss) on sale of properties: | (23) | 0 | |
| Other undisclosed net income | 2 | ||
| Net income (loss) attributable to parent: | (21) | 0 | |
| Other undisclosed net income available to common stockholders, basic | 41 | ||
| Net income available to common stockholders, diluted: | 21 | 0 | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 6/30/2019 | ||
|---|---|---|---|
| Net income (loss): | (21) | 0 | |
| Comprehensive income (loss), net of tax, attributable to parent: | (21) | 0 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.